Post-transplant infections

Pharmacotherapy of post-transplant viral infections.

BACKGROUND Management of a number of significant viral pathogens in transplant recipients remains challenging. OBJECTIVES To define an optimal antiviral approach to the management of cytomegalovirus (CMV), human herpes virus-6 (HHV-6), Epstein-Barr (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), and polyoma virus-associated nephropathy in transplant recipients. METHODS...

Post-transplant infections: single center experience from the developing world.

OBJECTIVE To describe our experience of post-transplant infections in allogeneic stem cell transplants at the Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan. METHODS From July 2001 to September 2006, patients with malignant and non-malignant hematological disorders having human leukocyte antigen (HLA)-matched sibling donors were selected for transplant. Pre-transplant infect...

Multi-Drug-resistant Organism (MDRO) Infections in Liver Transplant Recipients 30 Days Post-Transplant

Post-transplant hyperlipidaemia.

The correction of post-transplant hyperlipidaemia warrants the judicious and timely use of pharmacological agents with dietary modification and exercise. Reduction in hyperlipidaemia may have some role in decreasing the incidence of chronic rejection of allografts. The awareness that the morbidity and mortality of atherosclerotic disease may be lowered by active intervention will result in a be...

Post-transplant lymphoproliferative disorder.

BACKGROUND Posttransplant lymphoproliferative disorder (PTLD) is increasingly recognized as a serious complication of solid organ transplantation in both children and adults. Factors associated with increased risk of PTLD include mismatch of recipient and donor EBV serologic status (seronegative recipient with seropositive donor), and intensive drug-induced immunosuppression. METHODS AND RESU...